USE OF THE ASTRAZENECA VACCINE: ADVICE ON UPDATED JCVI STATEMENT

JCVI advises that, in addition to those aged under 30, unvaccinated adults aged 30 – 39 years who are not in a clinical priority group at higher risk of severe COVID-19 disease, should be preferentially offered an alternative to the AstraZeneca COVID-19 vaccine, where possible and only where no substantial delay or barrier in access to vaccination would arise.
  • For those under 40 years who are of older age, male, obese (BMI >30), from certain ethnic minority backgrounds or experiencing socio-economic deprivation, the risks of acquiring and/ or suffering complications of COVID-19 are higher. Every effort should be made to remove barriers to accessing vaccination in those individuals.
  • -For those aged 18-29 years the precautionary advice for a vaccine preference is stronger, reflecting a gradient in the benefit-risk balance with age.
 
This updated advice is specific to the current UK context and is contingent upon the current low incidence of COVID-19 disease, availability of alternatives to the AstraZeneca vaccine, and continued pace of vaccine rollout.
 
Importantly, this updated advice does not mean that JCVI advises against using the AstraZeneca vaccine in the 30 to 39 year cohort, only that an alternative is preferable when this would result in no substantial delay or barrier in access to vaccination would arise. JCVI have recognised that due to its storage and transport requirements, the AstraZeneca vaccine is much more easily delivered in some settings, and in these settings it may be the only vaccine it is practical to offer. In these circumstances JCVI have advised that the benefits of receiving the AstraZeneca vaccine continue to outweigh the risks, and individuals in this event should be offered the AstraZeneca vaccine.
 
Attached Official Statement from Department of Health includes –
 

UPDATED RECOMMENDATIONS AND ACTIONS NOW REQUIRED OF ALL VACCINATION PROVIDERS

  • Second doses
  • First doses for unvaccinated adults who are aged 30 to 39 years and are not in a clinical
  • Priority group at higher risk of COVID-19 disease
  • First doses for unvaccinated adults who are aged 30 to 39 years and are in a clinical priority
  • Group at higher risk of COVID-19 disease
  • First doses for unvaccinated adults who are aged 40 years or over

HSS MD 35 2021 USE OF THE ASTRAZENECA VACCINE ADVICE ON UPDATED JCVI STATEMENT